Anika Therapeutics, Inc. (ANIK)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 898437 · fiscal year ends in Dec
Closing price $20.90 on 30 Oct 2026; 52-week range $9.13 to $22.03.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $120.7M
- Revenue growth
- 5.3%
- Net income, last twelve months
- -$3.8M
- Earnings per share
- -$0.27
- Gross margin
- 62.2%
- Operating margin
- -4.2%
- Net margin
- -3.1%
- Free cash flow
- $562.0K
- Return on equity
- -2.8%
- Market value
- $279.7M
- Cash
- $38.4M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 13.4M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $112.8M | -$11.1M | -$10.9M | -$0.76 | $4.4M | 10-K filed 3 Mar 2026 |
| FY2024 | 31 Dec 2024 | $119.9M | -$5.1M | -$56.4M | -$3.83 | -$2.3M | 10-K filed 17 Mar 2025 |
| FY2023 | 31 Dec 2023 | $120.8M | $844.0K | -$82.7M | -$5.64 | -$7.2M | 10-K filed 15 Mar 2024 |
| FY2022 | 31 Dec 2022 | $113.8M | $3.7M | -$14.9M | -$1.02 | -$3.1M | 10-K filed 16 Mar 2023 |
| FY2021 | 31 Dec 2021 | $147.8M | $2.6M | $4.1M | $0.28 | $3.3M | 10-K filed 11 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $32.6M | $3.3M | $0.24 |
| Q1 FY2026 | 31 Mar 2026 | $29.6M | -$5.1M | -$0.37 |
| Q4 FY2025 | 31 Dec 2025 | $30.6M | $292.0K | $0.02 |
| Q3 FY2025 | 30 Sep 2025 | $27.8M | -$2.3M | -$0.16 |
| Q2 FY2025 | 30 Jun 2025 | $28.2M | -$4.0M | -$0.28 |
| Q1 FY2025 | 31 Mar 2025 | $26.2M | -$4.9M | -$0.34 |
| Q4 FY2024 | 31 Dec 2024 | $30.6M | -$21.9M | -$1.48 |
| Q3 FY2024 | 30 Sep 2024 | $29.6M | -$29.9M | -$2.03 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| OEM Channel | $64.4M | 57.1% |
| Commercial Channel | $48.4M | 42.9% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $70.1M | 62.1% |
| Europe | $22.2M | 19.7% |
| Other Location | $20.5M | 18.2% |
Company events
The newest 8-K filings of 202 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 29 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 14 Jul 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 23 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 29 Apr 2026 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 26 Feb 2026 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 8 Jan 2026 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 5 Nov 2025 | 8-K | Results, Other events | 2.02, 8.01, 9.01 |
| 30 Jul 2025 | 8-K | Results | 2.02, 9.01 |
| 30 Jul 2025 | 8-K | Investor update | 7.01, 9.01 |
| 24 Jun 2025 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 9 May 2025 | 8-K | Results | 2.02, 9.01 |
| 10 Apr 2025 | 8-K | Leadership change | 5.02 |
Every filing
The newest filings with the SEC of 474 held.
| Filed | Form | Period |
|---|---|---|
| 29 Jul 2026 | S-8 | – |
| 29 Jul 2026 | 10-Q | 30 Jun 2026 |
| 29 Jul 2026 | 8-K | 29 Jul 2026 |
| 14 Jul 2026 | 8-K | 10 Jul 2026 |
| 23 Jun 2026 | 8-K | 18 Jun 2026 |
| 8 Jun 2026 | DEFA14A | – |
| 1 Jun 2026 | DEFA14A | – |
| 30 Apr 2026 | 10-Q | 31 Mar 2026 |
| 29 Apr 2026 | 8-K | 24 Apr 2026 |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
| 28 Apr 2026 | DEFA14A | – |
| 28 Apr 2026 | DEF 14A | 18 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 4 Aug 2026 | Fischetti Gary P, Director | Purchase | 1,000 | $20.32 | $20.3K | 54,015 | 5 Aug 2026 |
| 3 Aug 2026 | Fischetti Gary P, Director | Purchase | 1,000 | $20.75 | $20.7K | 53,015 | 5 Aug 2026 |
| 1 May 2026 | Henneman John B Iii, Director | Purchase | 5,000 | $14.66 | $73.3K | 54,871 | 4 May 2026 |
| 30 Apr 2026 | Griffin Stephen D., President and CEO | Purchase | 12,200 | $12.29 | $149.9K | 36,163 | 30 Apr 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 7 Aug 2026 | Jellison William R, Former Director | 16,864 | $355.3K | 7 Aug 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 31 Jul 2026 | Vanguard Capital Management | 13G amended | 4.95% | 659.2K |
| 17 Jul 2026 | BlackRock Portfolio Management LLC | 13G amended | 4.1% | 544.7K |
| 29 Apr 2026 | Vanguard Capital Management | 13G | 5.19% | 695.7K |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 27 Jan 2026 | Caligan Partners LP | 13D amended | 9.95% | 1.4M |
| 8 Jan 2026 | Trigran Investments, Inc. | 13G amended | 1.2% | 168.4K |
| 21 Nov 2025 | Caligan Partners LP | 13D amended | 9.95% | 1.4M |
| 7 Nov 2025 | Trigran Investments, Inc. | 13G amended | 11.2% | 1.6M |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 27 Feb 2020 | Tom Malinowski (NJ07) | Purchase | $1,001 - $15,000 | 26 Aug 2021 |
| 28 Feb 2020 | Tom Malinowski (NJ07) | Purchase | $1,001 - $15,000 | 26 Aug 2021 |
| 29 Oct 2019 | Tom Malinowski (NJ07) | Sale (partial) | $1,001 - $15,000 | 26 Aug 2021 |
| 28 Jan 2020 | Tom Malinowski (NJ07) | Sale (partial) | $1,001 - $15,000 | 26 Aug 2021 |
| 29 Jul 2019 | Tom Malinowski (NJ07) | Sale (partial) | $1,001 - $15,000 | 26 Aug 2021 |
| 1 Aug 2019 | Tom Malinowski (NJ07) | Purchase | $50,001 - $100,000 | 26 Aug 2021 |
| 2 Mar 2020 | Tom Malinowski (NJ07) | Purchase | $1,001 - $15,000 | 5 Mar 2021 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 365.7K | -0.39% | 3.35 |
| 30 Sep 2026 | 367.2K | -3.73% | 4.42 |
| 15 Sep 2026 | 381.4K | +10.4% | 5.36 |
| 31 Aug 2026 | 345.4K | +2.44% | 2.7 |
| 14 Aug 2026 | 337.2K | +9.64% | 2.27 |
| 31 Jul 2026 | 307.6K | -12.07% | 4.34 |
| 15 Jul 2026 | 349.8K | -16.11% | 4.64 |
| 30 Jun 2026 | 417.0K | -1.89% | 4.89 |
Funds that hold it
From each fund's latest Form 13F.
145 funds held it at 30 Jun 2026: 63 added and 39 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 1,449,671 | $21.2M | -145,222 |
| Caligan Partners LP | 1,435,130 | $21.0M | 0 |
| Morgan Stanley | 614,320 | $9.0M | -257,746 |
| Acadian Asset Management LLC | 606,544 | $8.9M | 0 |
| Vanguard Capital Management LLC | 572,113 | $8.4M | -33,664 |
| AQR Capital Management LLC | 559,846 | $8.2M | +287,577 |
| Boothbay Fund Management, LLC | 529,640 | $7.7M | +137 |
| Renaissance Technologies LLC | 481,417 | $7.0M | -20,800 |
| Dimensional Fund Advisors LP | 451,095 | $6.6M | -7,752 |
| Capital Management Corp. | 448,474 | $6.6M | +753 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B